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Cytokine mediated changes in paracellular permeability contribute to a multitude of pathological conditions including chronic
rhinosinusitis (CRS). The purpose of this study was to investigate the effect of interferons and of Th1, Th2, and Th17 cytokines on
respiratory epithelium barrier function. Cytokines and interferons were applied to the basolateral side of air-liquid interface (ALI)
cultures of primary human nasal epithelial cells (HNECs) from CRS with nasal polyp patients. Transepithelial electrical resistance
(TEER) and permeability of FITC-conjugated dextrans were measured over time. Additionally, the expression of the tight junction
protein Zona Occludens-1 (ZO-1) was examined via immunofluorescence. Data was analysed using ANOVA, followed by Tukey
HSD post hoc test. Our results showed that application of interferons and ofTh1 orTh2 cytokines did not affect the mucosal barrier
function. In contrast, theTh17 cytokines IL-17, IL-22, and IL-26 showed a significant disruption of the epithelial barrier, evidenced
by a loss of TEER, increased paracellular permeability of FITC-dextrans, and discontinuous ZO-1 immunolocalisation.These results
indicate that Th17 cytokines may contribute to the development of CRSwNP by promoting a leaky mucosal barrier.
1. Introduction
Chronic rhinosinusitis (CRS) is characterized by severe
inflammation of the sinus mucosa leading to blockage of
the nasal passageway and the accumulation of mucus and
pathogens in the nose and paranasal sinuses [1, 2]. CRS affects
around 1.9 million Australians [3] and puts a large financial
burden on health care systems [4].
CRS is subdivided in CRS with nasal polyps (CRSwNP)
and CRS without nasal polyps (CRSsNP) based on the
presence or absence of polyps in the sinonasal cavities [5].
CRSwNP patients typically display a T helper 2 (Th2) polar-
ization, whereas patients without nasal polyps (CRSsNP) are
often characterized by a Th1 polarization with high levels of
Interferon-𝛾 [6].
Cytokines regulate innate and acquired immunity [7]
and can disrupt mucosal barrier function by altering tight
junction (TJ) composition and structure.This occurs through
signalling pathways independent of cell death and the effect
is cell type specific, pleiotropic, and time and dose-dependent
[8]. Relatively few studies have demonstrated cytokine effects
on nasal epithelial tissue or barrier function [5, 6, 9, 10]. Th1
cytokines such as interleukin-2 (IL-2), interferon-𝛾 (IFN-𝛾),
and Tumour Necrosis Factor alpha (TNF-𝛼) are the primary
source for proinflammatory Th1 responses [11], in which
they are effective in controlling infection with intracellular
pathogens and for perpetuating autoimmune responses [12].
In contrast, Th2 immune responses are characterized by the
production of the interleukins IL-4, IL-5, and IL-13 [13]
that are associated with the promotion of eosinophil recruit-
ment and activation, and inhibition of several macrophage
functions, thus providing phagocyte-independent protective
responses [14]. Th17 cells are a subset of activated CD4+
T cells and are characterized by the production of the
interleukins IL-17A, IL-17F, IL-22, and IL-26 [15]. Th17 cells
act as a bridge between adaptive and innate immunity where
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they play crucial roles in the development of autoimmunity,
inflammation, and allergic reactions [10]. Here, we tested
the effect of interferon proteins and of Th1, Th2, and Th17
cytokines on the mucosal barrier structure and function of
primary nasal epithelial cells harvested from nasal polyps of
CRS patients.
2. Methods
2.1. Harvesting and Culturing Human Nasal Epithelial Cells In
Vitro. Ethical approval for nasal brushing from CRS patients
was granted from the Queen Elizabeth Hospital Human
Ethics Committee and only consented patients were included
in the study. Exclusion criteria included active smoking, age
less than 18 years, and systemic disease. Primary human
nasal epithelial cells (HNECs) were harvested from nasal
polyps by gentle brushing in a method as described in
[16]. Extracted cells were suspended in Bronchial Epithelial
Growth Media (BEGM, CC-3170, Lonza, Walkersvill, MD,
USA), supplemented with 2% Ultroser G (Pall Corpora-
tion, Port Washington, NY, USA). The cell suspension was
depleted of monocytes using anti-CD68 (Dako, Glostrup,
Denmark) coated culture dishes, and HNECs expanded
in routine cell culture conditions of 37∘C humidified air
with 5% CO
2
in collagen coated flasks (Thermo Scientific,
Walthman, MA, USA). HNECs were tested at passage two
and confirmed to be of epithelial lineage via reactivity to
pan-Cytokeratin and CD45 antibodies (both from Abcam,
Cambridge, MA, USA), and a Diff-Quick staining method
used in the assessment of cell morphology by professional
cytologists (IMVS,TheQueen ElizabethHospital,Woodville,
Australia).
2.2. Air Liquid Interface Culture. HNEC were maintained at
an Air Liquid Interface (ALI) medium, following the Lonza
ALI culture method (Lonza, Walkersville, USA). Briefly,
Transwells (BD Biosciences, San Jose, California, USA) were
treated with collagen (Stemcell Technologies, Australia).
70,000 cells were seeded in a volume of 100 𝜇LB-ALImedium
into the apical chamber of the Transwell plate and 500𝜇L
of B-ALI growth medium was added to the basal chamber
in all wells containing the inserts. Cells were incubated at
37∘C. On day 3 after seeding, B-ALI growth medium was
removed from the apical and basal chambers and 500𝜇L B-
ALI differentiation medium was added to the basal chamber
only, exposing the apical cell surface to the atmosphere.
Regular examinations weremade to assess the integrity of the
cell layer.
2.3. Th1, Th2, and Th17 Cytokines Exposure. Cytokines were
added to the basal Transwell chamber at the following
final concentrations: recombinant human Interferon-
𝛾 (500 ng/mL, Sigma, Saint Louis, USA), interferon 𝛽
1a (50 ng/mL, Sigma, Saint Louis, USA), interferon-𝛼
(500 ng/mL, Sigma, Saint Louis, USA), Tumour Necrosis
Factor-𝛼 (500 ng/mL, Sigma, Saint Louis, USA), IL-1b
(500 ng/mL, Sigma, Saint Louis, USA), IL-4 (50 ng/mL,
Gibco, life Technology, USA), IL-5 (50 ng/mL, Gibco, Life
Technology, USA), IL-13 (50 ng/mL, Gibco, Life Technology,
USA), IL-17A (50 ng/mL, Gibco, Life Technology, USA),
recombinant human IL-22 (50 ng/mL, Sigma, Saint Louis,
USA), and recombinant human IL-26 (50 ng/mL, Abnova
Taiwan Corp).
2.4. Hematoxylin and Eosin (H&E) Staining and Histopatho-
logical Examination of Slides. Paraffin-embedded tissue sam-
ples were cut in 4 𝜇m thick sections on amicrotome (Thermo
Scientific HM 325 Rotary Microtome). Slides were then
stained with routine hematoxylin and eosin (H&E) staining
using Mayer’s Hematoxylin and Eosin (Lillie’s Modification,
Dako, Thermo Fisher Scientific, Waltham, MA, USA). All
slides were then scanned using digital whole-slide imaging
technology (WSI) on the NanoZoomer Digital Pathology
System (Hamamatsu Photonics, Hamamatsu City, Japan)
under high resolution (40x objective magnification power).
Eosinophil and neutrophil scoring was done according to a
systematized methodology as detailed in [17].
2.5. Transepithelial Electrical Resistance (TEER). Transep-
ithelial electrical resistance (TEER) was measured by using
an EVOM volt-ohmmeter (World Precision Instruments,
Sarasota, FL, USA). Briefly, 100 𝜇L of B-ALI medium was
added to the apical chamber of ALI cultures to form an
electrical circuit across the cell monolayer and into the
basal chamber. Cultures were maintained at 37∘C during
the measurement period using a heating platform. Only
wells displaying baseline resistance readings greater than
500Ω/cm2 were used for the experiments. Cytokines and
control (B-ALI medium for the negative control and 2%
Triton ×100 for the positive control) were added to the
bottom chamber of each well, and TEERmeasurements were
obtained at time 0, 4 h, and 24 h.
2.6. Permeability Assay. Paracellular permeability was stud-
ied by measuring the apical-to-basolateral flux of FITC dex-
tran 4 kDa (Sigma, Saint Louis, USA). Briefly, after treating
the cells for 24 h, the upper chambers were filled with
3mg/mL of FITC-dextran and incubated for 2 h at 37∘C.
40 𝜇L samples were recovered from the bottom chamber and
serially diluted on a 96-well plate (CorningCostar cell culture
plates (96 wells)), and the fluorescence was measured with
a microplate fluorometer (FLUOstar Optima, BMG Labtech,
Ortenberg, Germany).
2.7. Cytotoxicity Assay. The amount of lactate dehydrogenase
(LDH) in the medium was measured at 24 hours using the
CytotoxHomogeneousMembrane Integrity Assay (Promega,
Australia). Briefly, 50mL of the media from each well was
transferred to a new plate, and 50mL of LDH reagent was
added to the supernatant and incubated for 30 minutes in
the dark at room temperature. The OD was measured at
490 nmon a FLUOstar OPTIMAplate reader (BMGLabtech,
Ortenberg, Germany).
2.8. Trypan Blue Assay. After cell incubation with the
cytokines, the culture medium was discarded and washed
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with PBS, and 100 𝜇L of trypsin was added to each well.
The plate was incubated for 5 minutes, and then 250𝜇L of
supplemented culture medium was added. The contents of
each well were aspirated, placed into labeled microtubes,
and centrifuged at 1000 rpm for 5 minutes. The supernatant
was discarded, and the cells were suspended again in 100 𝜇L
of culture medium. An aliquot of 10 𝜇L of cell suspension
was removed and mixed with 10 𝜇L of Trypan Blue. After
homogenization, the live and dead cells were counted and the
percentage of viable cells was calculated.
2.9. Immunofluorescence Microscopy. Cells were fixed with
2.5% formalin in phosphate-buffered saline (PBS) for 10min,
and then the cells were rinsed with tris-buffered saline-0.5%
Tween (TBST) four times, permeabilizedwith 1% SDS in PBS,
and blocked with serum free blocker (SFB; Dako, Glostrup,
Denmark) for 60 minutes, at room temperature. Mouse
monoclonal anti-human ZO-1 (Invitrogen, Carlsbad, CA,
USA), diluted to 5 𝜇g/mL in TBST-10% SFB, was added to the
excised culture support membranes and allowed to incubate
for 1 hour at room temperature. Excess primary antibody
was removed with TBST, and 2𝜇g/mL anti-mouse Alexa-594
conjugated secondary antibody (Jackson ImmunoResearch
Labs Inc., West Grove, PA, USA) was then added for 1 hour at
room temperature. The filters were rinsed in TBST, and after
the third wash 200 ng/mL of 4󸀠,6-diamidino-2-phenylindole
(DAPI; Sigma, Aldrich) was added to resolve nuclei. Mem-
branes were rinsed once with ultrapure water, and 95% ice
cold ethanol was added for 1 hour at 4∘C. Membranes were
transferred to a glass slide and a drop of anti-fade mounting
medium (Dako,Glostrup,Denmark)was added before cover-
slipping. Sampleswere visualized by using a LSM700 confocal
laser scanning microscope (Zeiss Microscopy, Germany).
2.10. Statistical Analysis. Data are presented as mean ± SEM.
The TEER experiment was performed using three replicates
from four CRSwNP patients with values normalised against
the mean value from the patient at time 0. The dextran-
FITC assay was performed using three replicates from four
CRSwNP patients. Statistical analyses of all data were carried
out using ANOVA, followed by Tukey HSD post hoc test.
These tests were performed using SPSS software (version 18).
3. Results
3.1. Th17 Cytokines Disrupt TEER of HNECs. ALI cultures
were established from 4 independent CRS patient donors
(2 males and 2 females, aged 45–60 years). Two patients
were diagnosed with grass-pollen allergy, one had Aspirin-
Exacerbated Respiratory Disease (AERD), and two were
asthmatic. Eosinophil and neutrophil counts [11.1 (4.6–21.3)
and 0.8 (0–2.4)] per High Power Field (HPF) were not
different between the different patients (𝑝 > 0.05). The
effect of interferons and of Th1, Th2, and Th17 cytokines was
examined by measuring the TEER across HNECmonolayers
fromCRS patients at different time points. AllTh17 cytokines
tested (IL-17, IL-22 and IL-26) caused a significant reduction








































































Figure 1: The Th17 cytokines IL-17, IL-22, and IL-26 cause a time-
dependent reduction in TEER. Effect of Interferons 𝛼, 𝛽, and 𝛾
and of Th1, Th2, and Th17 cytokines on epithelial barrier func-
tion determined by measuring transepithelial electrical resistance
(TEER) before the addition of cytokines (𝑡 = 0), and after 4 and
24 h. The values are shown as mean ± SEM for 𝑛 = 4. Treatments
significantly different from the untreated control at 𝑝 < 0.05 are







































































Figure 2: TheTh17 cytokines cause an increase in paracellular per-
meability inCRS. Paracellular permeability ofHNECs inALI culture
was determined by aDextran-FITC assay after 24 h treatment ofTh1,
Th2, andTh17 cytokines. The values are shown as means ± SEM for
𝑛 = 4. Treatments significantly different from the untreated control
at 𝑝 < 0.05 are presented as ∗. ANOVA, followed by Tukey HSD
post hoc test.
IL-22, and IL-26 resp.) after 24 h of incubation. In contrast,
Th1 and Th2 cytokines or interferon 𝛼, 𝛽, or 𝛾 did not show
any significant effect on TEER (Figure 1).
3.2. Th17 Cytokines Increase the Paracellular Permeability of
HNECs. All IL-17 family cytokines (IL-17, IL-22, and IL-26)
led to a significant enhancement of paracellular permeability
(𝑝 < 0.05) (Figure 2). IL-17 had the strongest effect,
with 89.33% of the fluorescent dextran crossing the HNEC
monolayer whereas IL-22 and IL-26 increased paracellular
permeability with 49.85% and 53.92%, respectively. Th1 and
Th2 cytokines and interferons 𝛼, 𝛽, and 𝛾 did not show any
significant effect on the paracellular permeability in CRS
patients (Figure 2).




































































Figure 3: Th1, Th2, andTh17 cytokines and interferons do not have
cytotoxic effects on HNECs. Relative viability as determined by the
LDH assay after 24 h treatment of Th1, Th2, and Th17 on HNECs.
Cell viability was calculated relative to the untreated cells (0𝜇g/mL)
as negative control. The values are shown as means ± SEM, 𝑛 = 4.
3.3. Tight Junction Disruption Does Not Correlate with Cyto-
toxicity. The effect of interferons and of Th1, Th2, and Th17
cytokines on cellular toxicity was examined by measuring
LDH release from HNECs. There was no statistically signif-
icant increase in LDH release after 24 h incubation with any
of the cytokines (Figure 3). In addition, the cell density esti-
mated by the Trypan Blue assay did not show any significant
differences in cell density or cell viability in cytokine treated
cells compared to control cells (results not shown).
3.4. Th17 Cytokines Cause a Profound Disruption of the Tight
Junction Protein ZO-1. The effect of interferon proteins and
of Th1, Th2, and Th17 cytokines on the localization of Zona
Occludens-1 (ZO-1) was examined by using immunofluores-
cence staining and confocal laser scanning microscopy, 24
hours after application of the cytokines. In untreated cells,
ZO-1 was located at the periphery of the apical side of the
monolayer, as expected. Similarly, interferons 𝛼, 𝛽, and 𝛾 and
Th1 andTh2 cytokines, which had no effect on either TEER or
paracellular permeability, led to no alterations in the localiza-
tion of ZO-1. In contrast, application ofTh17 cytokines, which
significantly altered epithelial barrier function, resulted in
profound disruption of ZO-1 immunolocalisation evidenced
by faint or discontinuous regions of fluorescence (Figure 4).
4. Discussion
Cytokine mediated insult on mucosal membranes, causing
disruption of tight junctions and increased paracellular per-
meability, contributes to amultitude of pathologic conditions
in inflammatory diseases of the upper airways [18–20]. In this
study, we compared the effect of interferons and of signature
Th1, Th2, and Th17 cytokines on the barrier function of
primary nasal epithelial cells harvested from CRS patients
with nasal polyps. Immunolocalisation of the tight junction
protein ZO-1 was used to analyse tight junction integrity
to gain insights into mechanisms of cytokines dependent
disruption of the airway epithelial barrier.Our study indicates
that, in CRSwNP patients, IL-17 family cytokines (IL-17A,
IL-22, and IL-26) can significantly disrupt epithelial barrier
function in association with a disruption of tight junction
integrity and without causing cellular toxicity. In contrast,
Th1 and Th2 cytokines or interferons showed no significant
difference on either TEER or paracellular permeability of
HNECs.
It has been well established that different cytokines cause
different, often opposing effects on epithelial barrier function
depending on the cell type used and that any observed effect
is dose and time-dependent (reviewed in [8]). Our results
indicate that application of Th1 cytokines such as IFN-𝛾 and
TNF-𝛼 does not have detrimental effects on epithelial barrier
function. Rather, application of these cytokines appeared
to slightly enhance the TEER of human nasal epithelial
monolayers derived from some of the CRSwNP patients 24
hours after application. Whereas IFN-𝛾 and TNF-𝛼 generally
decrease barrier function in different cell lines [21, 22], in
airway epithelial cells, IFN-𝛾 has been reported to decrease
barrier function by Soyka et al. [5] and promote epithelial
barrier function by Ahdieh et al. [23]. These differences in
the response to IFN-𝛾 could be attributed to many factors
including interindividual variability in response to cytokines,
different origin of cells (mucosa or polyps), and differences in
experimental techniques. In the experiments by Soyka et al.
[5], for example, TEER changes in response to IFN-𝛾 treat-
ment fromCRSwNP,CRSsNPand controlswere pooledwhile
in our studies, only cells from CRSwNP were used. Given the
small number of samples used in most studies, further exper-
iments using a larger number of donors will need to address
the cause of these discrepancies. TNF-𝛼 can increase TEER
in mammalian uterine cell monolayers in a dose-dependent
manner [24]. Interestingly, a recent study revealed that
patients had developed a recurrence of CRS after the start of
TNF-𝛼 inhibitor administration with a remission of the dis-
ease only after cessation of TNF-𝛼 inhibitor treatment [25].
Moreover, we demonstrated no significant reduction of
TEER by Th2 family cytokines (IL-4, IL-5, and IL-13) after
4 h and 24 h in our experiments. Using airway epithelial cells,
Saatian et al. showed that IL-4 and IL-13 caused a reduction in
TEER 72 h after challenge but not after 24 h [26]. Soyka et al.
[5] also used airway epithelial cells from CRSwNP patients
(𝑛 = 2) and controls (𝑛 = 2) and similarly showed signif-
icantly decreased TEER after IL-4 challenge; however, this
effect was already evident after 12 and 24 hours. The reason
for these discrepancies is not clear and can be dependent on
numerous factors. While physiologically relevant, it is well
known that experiments using primary cells have limitations
due to inherent interindividual differences of age, genetic
make-up andmedical history [27].This is particularly impor-
tant in CRS, a multifactorial disease that can be associated
with Th1 or Th2 responses. Also ethnicity may play a role
as Caucasian CRSwNP patients are often characterised by a
predominant Th2 type eosinophilic inflammation with high
level of IL-5, whereas Asian CRSwNP patients preferentially
have a Th1/Th17 polarization signature [28].
Th17 cells play a significant role in chronic allergic
airway inflammation [29]. Th17 cytokines also affect the gut
mucosal barrier function by promoting the amplification of
the host response to secrete neutrophil chemoattractants and
antimicrobial peptides such as lipocalin-2 and calprotectin.
In addition, Th17 cells can expand within mucous layers in
association with the presence of pathogens that are resistant
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Figure 4: TheTh17 cytokines cause a profound disruption of the tight junction in CRS. Effect of IFN-𝛼, IFN-𝛽, IFN-𝛾, IL-1𝛽, TNF-𝛼, IL-4,
IL-5, IL-13, IL-17, IL-22, IL-26, and negative control on the localization of Zona Occludens-1 (ZO-1) (in red with DAPI stain in green) was
imaged with 20x objective power using immunofluorescence confocal laser scanning microscopy 24 hours after application of the cytokines.
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to some of the induced antimicrobial responses [30]. In
allergic rhinitis, serum IL-17 levels were significantly related
to clinical severity [31]. The expression level of IL-17 was
also shown to be significantly higher in recalcitrant CRSwNP
compared to controls [32]. In the present study, we found that
IL-17 induced barrier dysfunction as assessed by reduction in
TEER and enhanced macromolecular permeability, whereas
Soyka et al. showed that IL-17 had no influence on TEER [5].
We also demonstrated significant reductions in TEER and
enhanced macromolecular permeability of IL-22 and IL-26
which is the first such analysis using human nasal epithelial
cells.
In tight junction formation, ZO-1 plays an essential role,
by linking the transmembrane proteins occludin, claudin,
and Junction AdhesionMolecule (JAM) cytoplasmic compo-
nents of the tight junctions to the actin cytoskeleton [33]. Dis-
ruption of the actin-myosin structure has been understood to
modulate paracellular permeability [8]. We observed a loss
of normal ZO-1 immunolocalisation in HNEC monolayers
of CRSwNP patients secondary to challenge withTh17 (IL-17,
IL-22, and IL-26) cytokines, in association with disruption of
barrier function.We also observed that IL-17, IL-22, and IL-26
treated cells appeared in higher cell densities than cells treated
with other Th1 or Th2 family cytokines. It is known that
TJs regulate epithelial proliferation by different molecular
mechanisms, which generally suppress proliferation as cell
density (and hence TJ assembly) increases (reviewed in [34]).
Changes in expression of ZO-1 and ZO-1-associated nucleic
acid binding protein (ZONAB), a Y-box transcription factor,
affect cell proliferation; however, these effects take place at
least 48 hours after changes in gene expression [35]. Given
that the duration of exposure to the treatments in our
experiments was only 24 hours and that cell counts did not
show significant differences, we believe that TJ disruption
secondary to IL-17, IL-22, and IL-26 exposure might render
the pseudostratified layer of cells into a monolayer which
might appear relatively overcrowded.
In summary, in patients with CRSwNP, Th1 and Th2
cytokines showed no significant effect on epithelial barrier
structure and function. In contrast, the Th17 cytokines
family (IL-17, IL-22, and IL-26) showed significant disruption
of the epithelial barrier, leading to increased paracellular
permeability associated with reduced tight junctionintegrity.
In future studies, it will be important to determine the
cellular mechanism of the effect of Th17 cytokines on the
mucosal barrier in CRS patients to provide an opportunity
for therapeutic modulation in inflammatory stress.
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